sufentanil has been researched along with naltrexone in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 12 (44.44) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brockmöller, J; Friesacher, HR; Meyer, MJ; Neumann, VE; Tzvetkov, MV; Zdrazil, B | 1 |
| Freye, E; Latasch, L; Portoghese, PS | 1 |
| Blackford, SP; Kuhn, CM; Little, PJ | 1 |
| Mjanger, E; Yaksh, TL | 1 |
| Sharpe, LG | 1 |
| Mueller, J; Quock, RM | 1 |
| Gaumann, DM; Tyce, GM; Yaksh, TL | 1 |
| Beilin, B; Gale, RP; Liebeskind, JC; Martin, FC; Shavit, Y | 1 |
| Harty, GJ; Onofrio, BM; Yaksh, TL | 1 |
| Lazar, DF; Medzihradsky, F | 1 |
| Cheung, P; Li, JG; Liu-Chen, LY; Raffa, RB; Tzeng, TB | 1 |
| Hudson, S | 1 |
| Bigot-Viale, A; Granry, JC; Pierrot, M; Tesson, B; Vigue, JP | 1 |
| Meert, TF; Verborgh, C | 1 |
| Clark, MJ; Emmerson, PJ; Medzihradsky, F; Remmers, AE | 1 |
| Freye, E; Latasch, L; Schmidhammer, H | 1 |
| Ayesta, FJ; Díaz, A; Flórez, J; Hurlé, MA; Pazos, A; Santana, V | 1 |
| Freye, E; Latasch, L | 1 |
| Barrett, AC; Picker, MJ; Smith, ES | 1 |
| Freye, E; Levy, J | 1 |
| Gintzler, AR; Liu, NJ; von Gizycki, H | 1 |
| Hansen, C; Huizenga, M; Kreeger, TJ; Wise, BL | 1 |
| Kellie, KA; Kreeger, TJ | 1 |
| Wang, Z; Zhan, Y; Zhang, J; Zhao, Z | 1 |
1 review(s) available for sufentanil and naltrexone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
26 other study(ies) available for sufentanil and naltrexone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
Topics: Analgesics, Opioid; HEK293 Cells; Humans; Inhibitory Concentration 50; Models, Molecular; Organic Cation Transporter 1; Permeability; Protein Conformation | 2019 |
The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects.
Topics: Animals; Carbon Dioxide; Dogs; Dose-Response Relationship, Drug; Evoked Potentials, Somatosensory; Indoles; Morphinans; Naltrexone; Narcotic Antagonists; Neurons, Afferent; Nociceptors; Oxygen; Receptors, Opioid; Receptors, Opioid, delta; Respiration; Sufentanil | 1992 |
Mu- and kappa-opiate receptor control of prolactin secretion in rats: ontogeny and interaction with serotonin.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Aging; Animals; Cyproheptadine; Female; Kinetics; Male; Naltrexone; Prolactin; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Serotonin; Sufentanil | 1992 |
Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Topics: Analgesics; Animals; Binding, Competitive; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Fentanyl; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, mu; Spinal Cord; Sufentanil | 1991 |
Separate neural mechanisms mediate sufentanil-induced pupillary responses in the cat.
Topics: Analgesics, Opioid; Animals; Cats; Clonidine; Drug Interactions; Fentanyl; Male; Morphine; Mydriasis; Naltrexone; Pupil; Receptors, Opioid; Receptors, Opioid, mu; Sufentanil | 1991 |
Protection by U-50,488H against beta-chlornaltrexamine antagonism of nitrous oxide antinociception in mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesia; Analgesics; Animals; Fentanyl; Male; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Nitrous Oxide; Pain; Pyrrolidines; Sufentanil | 1991 |
Effects of sufentanil and naltrexone on adrenal vein catecholamines and neuropeptides during splanchnic nerve stimulation in cats.
Topics: Adrenal Glands; Analgesics; Animals; Blood Pressure; Catecholamines; Cats; Electric Stimulation; Fentanyl; Heart Rate; Naltrexone; Neuropeptides; Splanchnic Nerves; Sufentanil; Veins | 1990 |
Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats.
Topics: Anesthesia; Cytotoxicity Tests, Immunologic; Dose-Response Relationship, Drug; Fentanyl; Interferons; Killer Cells, Natural; Morphine; Naltrexone; Sufentanil; Time Factors | 1989 |
High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.
Topics: Anesthesia, Spinal; Animals; Blood Pressure; Cats; Drug Tolerance; Fentanyl; Hyperesthesia; Methadone; Morphine; Morphine Derivatives; Naltrexone; Rats; Receptors, Drug; Stimulation, Chemical; Strychnine; Sufentanil; Sulfates; Touch | 1986 |
Altered transition between agonist- and antagonist-favoring states of mu-opioid receptor in brain membranes with modified microviscosity.
Topics: Animals; Brain; Cholesterol Esters; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Etorphine; Male; Membrane Fluidity; Membranes; Naltrexone; Oleic Acid; Oleic Acids; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Sodium Chloride; Sufentanil; Viscosity | 1993 |
Apparent thermodynamic parameters of ligand binding to the cloned rat mu-opioid receptor.
Topics: Analgesics; Animals; Binding, Competitive; CHO Cells; Cricetinae; Diprenorphine; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Fentanyl; Ligands; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Pentazocine; Peptide Fragments; Peptides; Radioligand Assay; Rats; Receptors, Opioid, mu; Somatostatin; Sufentanil; Thermodynamics; Time Factors | 1998 |
Reentry using naltrexone: one anesthesia department's experience.
Topics: Humans; Kentucky; Licensure, Nursing; Naltrexone; Narcotic Antagonists; Narcotics; Nurse Anesthetists; Occupational Health Services; Opioid-Related Disorders; Peer Group; Professional Impairment; Program Evaluation; Sufentanil | 1998 |
[Interactions between naltrexone, an opioid antagonist, and opioids administered during general anesthesia].
Topics: Alcoholism; Analgesics, Opioid; Anesthesia, Intravenous; Anesthetics, Intravenous; Drug Interactions; Female; Humans; Hysterectomy; Middle Aged; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Sufentanil | 1999 |
The effects of intravenous naltrindole and naltrindole 5'-isothiocyanate on sufentanil-induced respiratory depression and antinociception in rats.
Topics: Analgesics, Opioid; Animals; Depression, Chemical; Hydrogen-Ion Concentration; Hypercapnia; Hypoxia; Isothiocyanates; Male; Naltrexone; Narcotic Antagonists; Pain Measurement; Rats; Rats, Wistar; Reaction Time; Receptors, Opioid, mu; Respiration; Sufentanil | 1999 |
Membrane microviscosity modulates mu-opioid receptor conformational transitions and agonist efficacy.
Topics: Animals; Cell Line; Cell Membrane; Cholesterol Esters; Diprenorphine; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Glioma; Guanosine 5'-O-(3-Thiotriphosphate); Membrane Fluidity; Nalbuphine; Naltrexone; Narcotic Antagonists; Narcotics; Neuroblastoma; Protein Conformation; Rats; Receptors, Opioid, mu; Sodium Chloride; Sufentanil; Tumor Cells, Cultured; Viscosity | 1999 |
14-methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog.
Topics: Anesthetics, Intravenous; Animals; Blood Pressure; Bradycardia; Carbon Dioxide; Depression, Chemical; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Hypnotics and Sedatives; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Oxygen; Pain Measurement; Respiratory Mechanics; Sufentanil | 2000 |
Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism.
Topics: Analgesics, Opioid; Animals; Arrestins; beta-Adrenergic Receptor Kinases; beta-Arrestin 2; beta-Arrestins; Blotting, Western; Brain; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; G-Protein-Coupled Receptor Kinase 3; G-Protein-Coupled Receptor Kinases; Male; Naltrexone; Narcotic Antagonists; Pain Measurement; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Receptors, Opioid, mu; Respiration; Spinal Cord; Sufentanil; Time; Tissue Distribution | 2002 |
Sufentanil-related respiratory depression and antinociception in the dog. Mediation by different receptor types.
Topics: Analgesics, Opioid; Animals; Blood Gas Analysis; Depression, Chemical; Dogs; Dose-Response Relationship, Drug; Evoked Potentials; Injections, Intraventricular; Male; Naltrexone; Narcotic Antagonists; Neurons, Afferent; Oxygen; Oxygen Consumption; Receptors, Opioid, delta; Receptors, Opioid, mu; Sufentanil | 2002 |
Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Topics: Animals; Cinnamates; Columbidae; Female; Fentanyl; Methadone; Morphine; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Narcotics; Reaction Time; Receptors, Opioid, mu; Sufentanil | 2003 |
Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal.
Topics: Acute Disease; Animals; Biotransformation; Dogs; Evoked Potentials, Somatosensory; Naltrexone; Narcotics; Protein Kinase C; Receptors, Opioid; Somatoform Disorders; Substance Withdrawal Syndrome; Sufentanil | 2005 |
Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine.
Topics: Animals; Animals, Newborn; Antibodies; Dose-Response Relationship, Drug; Dynorphins; Female; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Neural Pathways; Orchiectomy; Ovariectomy; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Factors; Spinal Cord; Sufentanil; Virilism | 2007 |
Sufentanil and xylazine immobilization of Rocky Mountain elk.
Topics: Adjuvants, Anesthesia; Anesthesia Recovery Period; Animals; Blood Gas Analysis; Deer; Female; Immobilization; Male; Muscle Relaxants, Central; Naltrexone; Narcotic Antagonists; Sufentanil; Xylazine | 2011 |
Sufentanil citrate immobilization of Alaskan moose calves.
Topics: Alaska; Anesthesia Recovery Period; Animals; Animals, Newborn; Animals, Wild; Deer; Dose-Response Relationship, Drug; Female; Fentanyl; Immobilization; Male; Naltrexone; Narcotics; Oxygen; Respiration; Sufentanil; Time Factors; Tolazoline; Xylazine | 2012 |
Effect of Sufentanil Combined with Nalmefene Assisted Surface Anesthesia on Transnasal Endotracheal Intubation Guided by Fiberoptic Bronchoscope.
Topics: Anesthesia; Bronchoscopes; Fiber Optic Technology; Humans; Intubation, Intratracheal; Naltrexone; Retrospective Studies; Sufentanil | 2022 |